Intelligence · Clinical Development
Pipeline search results
Programs matching “treatment” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 270 pipeline programs matching "treatment" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
MK-3475-B60
Fondazione Telethon ETS
Advanced unresectable classic Kaposi sarcoma relapsed and/or refractory to previous standard treatments.
1 trial -
MK-3475-B99
Merck Sharp and Dohme
First-line treatment of participants with extensive-stage small cell lung cancer
1 trial -
Mektovi film-coated tablets for metastatic colorectal cancer wi…
Disc Medicine
metastatic colorectal cancer with a proven RAS mutation after failure of standard systemic treatment regimens including at least 5- FU/capecitabine-oxaliplatin and irinotecan based standard treatment (unless contra-indications for either oxaliplatin or irinotecan)
1 trial -
Mifepristone 1200 mg daily
CORCEPT THERAPEUTICS INC
Treatment-resistant PTSD
1 trial -
NV-5138
SUPERNUS PHARMACEUTICALS, INC.
Treatment Resistant Depression
1 trial -
Nilotinib followed by treatment-free
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia
1 trial -
ORMD-0801 Treatment A
ORAMED PHARMACEUTICALS INC.
Type 1 Diabetes
1 trial -
Organoid-guided treatment
The First People's Hospital of Lianyungang
HER2-negative Breast Cancer
1 trial -
PCN-101
Chongqing Precision Biotech Co., Ltd
Treatment Resistant Depression
1 trial -
PERLA
Zentiva k.s.
Patients with moderate or severe oedema on a long-term treatment with amlodipine
1 trial -
PRODIGE 107-ENGIC01-COLOSOTO
NORTHWEST BIOTHERAPEUTICS INC
Colorectal Carcinoma
1 trial -
Pimavanserin
Acadia Pharmaceuticals B.V.
Treatment of Depression in Adults With Parkinson's Disease (PD)
1 trial -
Preoperative lanreotide treatment
The First People's Hospital of Lianyungang
Acromegaly
1 trial -
Psilocybin
COGNITION THERAPEUTICS INC
Treatment Resistant Depression
1 trial -
Psilocybin
Compass Therapeutics
Treatment-Resistant Major Depressive Disorder
1 trial -
RC48- ADC
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance
1 trial -
Radotinib HCl, Placebo for Radotinib HCl
Alphapharm Pty Ltd
Treatment of Parkinson’s disease (PD)
1 trial -
SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor
Lacuna Pharma Pty Ltd
Hypercortisolism related to benign adrenal tumour
1 trial -
Sibeprenlimab, Sibeprenlimab placebo
Otsuka Beijing Research Institute
Treatment of Sjögren’s disease
1 trial -
Sintilimab injection plus Inlyta treatment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Carcinoma, Renal Cell
1 trial -
Standard Cognitive Behavioral Treatment
BRIGHT MINDS BIOSCIENCES INC.
Substance-Related Disorders
1 trial -
Standard Treatment As Usual (TAU)
BRIGHT MINDS BIOSCIENCES INC.
Substance Abuse
1 trial -
TAK-653
Takeda
Treatment-Resistant Depression
1 trial -
TEMOZOLOMIDE
Istituto Gentili S.r.l.
Patients with well differentiated neuroendocrine neoplasia (NENs) not eligible for active antitumoral treatments due to their clinical conditions.
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.